Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > Highly Selective Prmt5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Highly Selective Prmt5 Inhibitor SYH2045 Obtains Clinical Trial Approval

January 04, 2023


202301.png

202302.png


Previous: Meloxicam Nanocrystal Injection Obtains Clinical Trial Approval

Next: CSPC's Innovative Drug Research Results Selected for the 2022 ASH Annual Meeting

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat